Jian Xie compensation by year
Fulgent Genetics Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $205,397 | $210,000 | $495,920 | $611,875 | $615,000 | $615,000 | $615,000 |
| Bonus | $0 | $8,000 | $200,000 | $0 | $0 | $0 | $0 |
| Stock awards | $657,400 | $5,684,000 | $0 | $3,115,000 | $922,500 | $1,537,500 | $1,845,000 |
| Option awards | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Non-equity incentive | $0 | $0 | $0 | $131,651 | $241,541 | $208,116 | $334,037 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $6,162 | $6,540 | $8,700 | $12,200 | $12,200 | $15,179 | $13,621 |
| Total | $868,959 | $5,908,540 | $704,620 | $3,870,726 | $1,791,241 | $2,375,795 | $2,807,658 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Fulgent Genetics, Inc. DEF 14A filed March 31, 2026, accession 0001674930-26-000020, and prior-year filings.
How this page was built: the Fulgent Genetics, Inc. filed document, accession 0001674930-26-000020. Every figure is read from that document and cited to the page and table it appears in. Filed March 31, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 157,245 | $4,130,826 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Fulgent Genetics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
7 Form 4 lines since the FY2025 proxy (filed March 31, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-10-26 | Tax withholding | — | 4,361 | $20.22 | 355,563 |
| 2026-09-02 | Sale | — | 2,127 | $19.66 | 359,924 |
| 2026-08-27 | Sale | — | 1,193 | $19.91 | 362,051 |
| 2026-07-26 | Tax withholding | — | 4,361 | $19.67 | 363,244 |
| 2026-06-02 | Sale | — | 2,146 | $17.89 | 367,605 |
| 2026-05-27 | Sale | — | 1,201 | $17.60 | 369,751 |
| 2026-04-26 | Tax withholding | — | 4,361 | $16.31 | 370,952 |
The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Fulgent Genetics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Ming Hsieh | Chief Executive Officer and Chairperson of the Board | $6,207,000 |
| Jian Xie · this page | President and Chief Operating Officer | $2,807,658 |
| Paul Kim | Chief Financial Officer | $2,773,352 |
| Hanlin Gao | Chief Scientific Officer and Laboratory Director | $2,352,249 |
The full Fulgent Genetics compensation record
free company briefThis page is one person within Fulgent Genetics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Fulgent Genetics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Fulgent Genetics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Fulgent Genetics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.